Trending...
- Tacoma Dome Welcomes Class of 2026
- From Broken to Soaring Week 40
- City of Tacoma Launches 'Tidy-Up Tacoma: Summer 2026' With Major Gateway Cleanup Effort
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- What Would you Do with Your Time if it Was Actually Money?
- Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
- City of Tacoma Presents Updated Financial Forecast as Next Step in 'Roadmap to Recovery' to Navigate National Economic Pressures
- Tacoma: Full Intersection Closure at E. 11th Street and St. Paul Avenue for One-Day Asphalt Repairs on June 27
- Spokane: Early-Morning House Fire Damages Two Homes on East Sanson Avenue
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
- Appliance EMT Launches June "Summer Rescue" Promotion
- New Luxury Single Family Homes From $976,990 in Manalapan
- Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
- K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
- HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
- KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
- School Dental Screening Programs Conducted in Dubai
- British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
- Looking for expert pool tiling in Gold Coast? Call Avid Tiling
- SPD Investigate Homicide In North Spokane - One Male In Custody
- Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
- Tacoma: Hylebos Bridge to Close for Five Hours on June 11 for Centerlock Replacement
- Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
- PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators
- Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
- Washington State High School Students Launch Virtual Rocketry Summit
- The Problem With AI Isn't Compute. It's Memory
- Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
- Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference